117 related articles for article (PubMed ID: 2409349)
1. Pregnancy-associated plasma protein A and extensive necrosis. Clinically significant predictors of early recurrence in stage I estrogen receptor-negative breast carcinoma.
Kuhajda FP; Eggleston JC
Lab Invest; 1985 Jul; 53(1):101-7. PubMed ID: 2409349
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy-associated plasma protein A. A clinically significant predictor of early recurrence in stage I breast carcinoma is independent of estrogen receptor status.
Kuhajda FP; Eggleston JC
Am J Pathol; 1985 Nov; 121(2):342-8. PubMed ID: 2414998
[TBL] [Abstract][Full Text] [Related]
3. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
4. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
6. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
[TBL] [Abstract][Full Text] [Related]
7. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
[TBL] [Abstract][Full Text] [Related]
9. Pregnancy-associated plasma protein A: a clinically significant predictor of early recurrence in stage II breast carcinoma.
Kuhajda FP; Abeloff MD; Eggleston JC
Hum Pathol; 1985 Mar; 16(3):228-35. PubMed ID: 2579017
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
13. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
Mansell J; Monypenny IJ; Skene AI; Abram P; Carpenter R; Gattuso JM; Wilson CR; Angerson WJ; Doughty JC
Breast Cancer Res Treat; 2009 Sep; 117(1):91-8. PubMed ID: 19112615
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
[TBL] [Abstract][Full Text] [Related]
15. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
Shao ZM; Wu J; Shen ZZ; Nguyen M
Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
[TBL] [Abstract][Full Text] [Related]
16. Prediction of recurrence for advanced breast cancer. Traditional and contemporary pathologic and molecular markers.
Masood S
Surg Oncol Clin N Am; 1995 Oct; 4(4):601-32. PubMed ID: 8535901
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
[TBL] [Abstract][Full Text] [Related]
18. Effect of margins on ipsilateral breast tumor recurrence after breast conservation therapy for lymph node-negative breast carcinoma.
Leong C; Boyages J; Jayasinghe UW; Bilous M; Ung O; Chua B; Salisbury E; Wong AY
Cancer; 2004 May; 100(9):1823-32. PubMed ID: 15112262
[TBL] [Abstract][Full Text] [Related]
19. [Breast-conservation treatment for early invasive breast cancer: prognostic factors for survival after salvage treatment of local recurrence].
Fodor J
Magy Onkol; 2007; 51(2):127-31. PubMed ID: 17660868
[TBL] [Abstract][Full Text] [Related]
20. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence.
Shen J; Hunt KK; Mirza NQ; Buchholz TA; Babiera GV; Kuerer HM; Bedrosian I; Ross MI; Ames FC; Feig BW; Singletary SE; Cristofanilli M; Meric-Bernstam F
Cancer; 2005 Aug; 104(3):479-90. PubMed ID: 15968686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
